FluGen, Inc. articles

MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old. This study is the first of its kind

• Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population –
• Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022 –

MADISON, Wis., June 22, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the dosing of i

• Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain –

MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company’s investigational, supra-seasonal, li

Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older adults, a population most vulnerable to mortality from flu –

Safety and immunogenicity study expected to begin in Q2 2022 –

MADISON, Wis., July 1, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory disea

Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu –

Topline data expected in 1H 2022 –

MADISON, Wis., May 25, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the initiation of the first study in older adults of M2SR, the company’s investigational supr

MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu.

UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this

CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR.

Abstract
Both influenza A and B viruses cause outbreaks of seasonal influenza resulting in significant morbidity and mortality. There are two antigenically distinct lineages of influenza B virus, Yamagata lineage (YL) and Victoria lineage (VL). Since both B lineages have been co-circulating for years, more than 70% of influenza vaccines currently manufactured are quadrivalent consisting of influenza A (H1N1), influenza A (H3N2), influenza B (YL) and influenza B (VL) anti